Karuna Therapeutics, Inc. (KRTX)

Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update. “2023 was a landmark year for Karuna, marked by the FDA acceptance of our NDA for KarXT for the treatment of schizophrenia in adults, with.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna Therapeutics, Inc. (NasdaqGM: KRTX) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Karuna will receive $330.00 in cash for each share of Karuna that they own. KSF is seeking to determine whether this consideration and the process that led to it.

Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna Therapeutics, Inc. (NasdaqGM: KRTX) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Karuna will receive $330.00 in cash for each share of Karuna that they own. KSF is seeking to determine whether this consideration and the process that led to it.

The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.

Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.

The holiday shopping season isn't over yet. A 3-D printing company and a major pharmaceuticals maker announced post-Christmas acquisitions Tuesday morning.

Karuna Therapeutics Inc (NASDAQ: KRTX) ended nearly 50% up on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biopharmaceutical firm for $14 billion.

NEW YORK , Dec. 22, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Karuna Therapeutics, Inc. (NASDAQ: KRTX) and its board of directors concerning the proposed acquisition of the company by Bristol Myers Squibb (NYSE: BMY). Stockholders will receive $330.00 for each share of Karuna Therapeutics stock that they hold.

Shares of biopharmaceutical company Karuna Therapeutics skyrocketed more than 47% Friday morning after giant Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) announced a deal to acquire the company in a $14 billion cash deal.  The agreement valued Karuna at $330 per share.

U.S. equities headed into the long holiday weekend with gains at midday, amid a broad-based rally fueled by enthusiasm over the possibility of several Fed interest rate cuts next year. The Dow, S&P 500, and Nasdaq were all up.

Karuna Therapeutics (KRTX) shares skyrocketed over 46% after Bristol Myers Squibb (BMY) said it would buy the biopharmaceutical firm for $14 billion to expand its neuroscience portfolio.

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

MILWAUKEE , Dec. 22, 2023 /PRNewswire/ -- Ademi LLP is investigating Karuna (NASDAQ: KRTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol-Myers. Click here to learn how to join the https://www.ademilaw.com/case/karuna-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.